Abstract
Background: The feasibility and efficacy of adjuvant hepatic arterial infusion (HAI) in preventing the development of liver metastases in patients with advanced colon carcinoma have not been validated. The aim of this randomized controlled study was to compare the feasibility of HAI and the protective effect against liver metastasis after curative resection to those of systemic chemotherapy. Methods: Between July 2000 and June 2003, 91 patients were enrolled. Patients were randomly assigned to receive 5-fluorouracil (5-FU) via continuous venous infusion (CVI) or intra-hepatic arterial weekly high-dose 5-FU (WHF). The primary endpoint was overall survival (OS). Results: In the WHF group, the cumulative failure rate of hepatic arterial catheterization was 16.7% at 6 months. The occurrence of grade 3 adverse events was comparable between the groups. The 5-year OS rates were 59.0% in the CVI group and 34.9% in the WHF group (P = 0.164). CVI tended to show a protective effect against liver metastasis regarding the 5-year liver-specific cumulative recurrence rate: CVI, 45.0% vs. WHF, 68.3%; P = 0.037). Conclusion: HAI therapy has a certain protective effect against liver metastasis after curative resection in patients with colorectal cancer. However, this therapy did not contribute to any marked improvement in their overall survival.
| Original language | English |
|---|---|
| Pages (from-to) | 84-90 |
| Number of pages | 7 |
| Journal | Journal of Cancer Research and Therapeutics |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2017 Jan 1 |
Fingerprint
Keywords
- Adjuvant chemotherapy
- Colorectal cancer
- Hepatic arterial infusion
- Liver metastasis
- Prognosis
ASJC Scopus subject areas
- Medicine(all)
- Oncology
- Radiology Nuclear Medicine and imaging
Cite this
Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma : JFMC 29-0003. / Kusano, Mitsuo; Honda, Michitaka; Okabayashi, Koji; Akimaru, Koho; Kino, Syuichi; Tsuji, Yasushige; Watanabe, Masashi; Suzuki, Satoshi; Yoshikawa, Takaki; Sakamoto, Junichi; Oba, Koji; Saji, Shigetoyo.
In: Journal of Cancer Research and Therapeutics, Vol. 13, No. 1, 01.01.2017, p. 84-90.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma
T2 - JFMC 29-0003
AU - Kusano, Mitsuo
AU - Honda, Michitaka
AU - Okabayashi, Koji
AU - Akimaru, Koho
AU - Kino, Syuichi
AU - Tsuji, Yasushige
AU - Watanabe, Masashi
AU - Suzuki, Satoshi
AU - Yoshikawa, Takaki
AU - Sakamoto, Junichi
AU - Oba, Koji
AU - Saji, Shigetoyo
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Background: The feasibility and efficacy of adjuvant hepatic arterial infusion (HAI) in preventing the development of liver metastases in patients with advanced colon carcinoma have not been validated. The aim of this randomized controlled study was to compare the feasibility of HAI and the protective effect against liver metastasis after curative resection to those of systemic chemotherapy. Methods: Between July 2000 and June 2003, 91 patients were enrolled. Patients were randomly assigned to receive 5-fluorouracil (5-FU) via continuous venous infusion (CVI) or intra-hepatic arterial weekly high-dose 5-FU (WHF). The primary endpoint was overall survival (OS). Results: In the WHF group, the cumulative failure rate of hepatic arterial catheterization was 16.7% at 6 months. The occurrence of grade 3 adverse events was comparable between the groups. The 5-year OS rates were 59.0% in the CVI group and 34.9% in the WHF group (P = 0.164). CVI tended to show a protective effect against liver metastasis regarding the 5-year liver-specific cumulative recurrence rate: CVI, 45.0% vs. WHF, 68.3%; P = 0.037). Conclusion: HAI therapy has a certain protective effect against liver metastasis after curative resection in patients with colorectal cancer. However, this therapy did not contribute to any marked improvement in their overall survival.
AB - Background: The feasibility and efficacy of adjuvant hepatic arterial infusion (HAI) in preventing the development of liver metastases in patients with advanced colon carcinoma have not been validated. The aim of this randomized controlled study was to compare the feasibility of HAI and the protective effect against liver metastasis after curative resection to those of systemic chemotherapy. Methods: Between July 2000 and June 2003, 91 patients were enrolled. Patients were randomly assigned to receive 5-fluorouracil (5-FU) via continuous venous infusion (CVI) or intra-hepatic arterial weekly high-dose 5-FU (WHF). The primary endpoint was overall survival (OS). Results: In the WHF group, the cumulative failure rate of hepatic arterial catheterization was 16.7% at 6 months. The occurrence of grade 3 adverse events was comparable between the groups. The 5-year OS rates were 59.0% in the CVI group and 34.9% in the WHF group (P = 0.164). CVI tended to show a protective effect against liver metastasis regarding the 5-year liver-specific cumulative recurrence rate: CVI, 45.0% vs. WHF, 68.3%; P = 0.037). Conclusion: HAI therapy has a certain protective effect against liver metastasis after curative resection in patients with colorectal cancer. However, this therapy did not contribute to any marked improvement in their overall survival.
KW - Adjuvant chemotherapy
KW - Colorectal cancer
KW - Hepatic arterial infusion
KW - Liver metastasis
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85019707924&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019707924&partnerID=8YFLogxK
U2 - 10.4103/0973-1482.184524
DO - 10.4103/0973-1482.184524
M3 - Article
C2 - 28508838
AN - SCOPUS:85019707924
VL - 13
SP - 84
EP - 90
JO - Journal of Cancer Research and Therapeutics
JF - Journal of Cancer Research and Therapeutics
SN - 0973-1482
IS - 1
ER -